Published on 21/12/2025
How One Sponsor Achieved IND Clearance for a First-in-Human Trial
Background: The Investigational Product and Sponsor Profile
This case study highlights a mid-sized biotechnology company preparing to enter clinical trials with a novel small-molecule kinase inhibitor. The molecule was developed to treat relapsed/refractory acute myeloid leukemia (AML) and showed strong preclinical efficacy across multiple cell lines and animal models.
With limited internal regulatory resources and a tight development timeline, the sponsor partnered with a global regulatory consultancy to plan, prepare, and submit the Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA).
To benchmark global trial standards, the team also reviewed historical data and protocols on platforms like ClinicalTrials.gov.
Key Objective: Initiate a Safe and Compliant First-in-Human Study
The company’s goal was to gain FDA clearance for a Phase 1, first-in-human (FIH) dose-escalation study in adult patients with AML. This
- Nonclinical pharmacology and toxicology data
- Chemistry, Manufacturing, and Controls (CMC) documentation
- A scientifically justified and risk-mitigated clinical protocol
A key challenge was ensuring that the starting dose was safe yet scientifically meaningful — without triggering a clinical hold.
Timeline and Strategy
The project was executed over a 9-month timeline:
- Month 1–3: Data gap analysis and development planning
- Month 4–6: Conduct of GLP toxicology studies and CMC process scale-up
- Month 7: Pre-IND meeting request and preparation
- Month 8: Finalization of IND modules
- Month 9: eCTD publishing and submission
Pre-IND Meeting Highlights
The sponsor held a Type B Pre-IND meeting with the FDA 60 days prior to submission. Key topics discussed included:
- Acceptability of 28-day toxicology data from rats and dogs
- Stability data required for a 12-week trial duration
- Proposed starting dose and escalation scheme
The FDA agreed in principle with the development plan but requested clarification on cardiac safety and hERG data, which the sponsor promptly addressed.
Sample Table: Nonclinical Toxicology Summary
| Species | Study Type | Duration | NOAEL (mg/kg/day) | Findings |
|---|---|---|---|---|
| Rat | Repeat-dose toxicity | 28 Days | 10 | Reversible hepatocellular hypertrophy |
| Dog | Repeat-dose toxicity | 28 Days | 3 | No significant toxicity |
IND Submission, FDA Review, and Trial Launch
Final IND Submission Package: Key Inclusions
The final IND submission included the following:
- Module 1: FDA Forms 1571 and 1572, Cover Letter, IRB documentation
- Module 2: Overall summaries for quality, nonclinical, and clinical
- Module 3: Drug substance and drug product data, process controls, stability
- Module 4: Full study reports of pharmacology, TK/PK, genotoxicity, and 28-day toxicity
- Module 5: Draft clinical protocol, investigator brochure, clinical monitoring plan
eCTD publishing was performed using validated commercial tools. Prior to uploading via the FDA ESG, the submission was run through the agency’s validation criteria checklist to ensure formatting and metadata compliance.
FDA Review Outcome
The FDA completed its 30-day review without issuing a clinical hold. However, the agency sent an Information Request (IR) asking for:
- Clarification on analytical method validation for assay accuracy
- Justification for dose escalation intervals
The sponsor responded within 5 business days with detailed data tables, redlined protocol updates, and analytical certificates.
FDA confirmed IND activation on Day 29, allowing the trial to initiate as planned.
Early Clinical Trial Success and Learning
The first patient was dosed within 45 days of IND clearance. The clinical team used a standard 3+3 dose escalation design with intensive safety monitoring, including cardiac telemetry, liver function testing, and daily vitals.
By the third dosing cohort, early signs of biological activity were observed, supporting further dose expansion in subsequent trial phases.
Key Lessons Learned from the IND Process
- Early gap analysis of nonclinical data saved critical time during finalization
- Engaging the FDA early helped prevent major CMC or protocol redesign later
- Strong project management was key to aligning cross-functional contributors
- Clear documentation and consistent formatting ensured a smooth review
Case Impact and Broader Application
The successful clearance of this IND allowed the sponsor to raise additional Series B funding, initiate patient enrollment across four U.S. sites, and submit a parallel CTA in Canada.
The strategy, tools, and team structure used in this case were later replicated across two additional INDs for other oncology programs within the same company.
Conclusion: A Roadmap for IND Success
This case study demonstrates that a well-executed IND submission — grounded in scientific integrity, robust planning, and regulatory engagement — can lead to smooth FDA clearance, rapid trial initiation, and long-term program momentum.
Whether you’re a small biotech or a multinational sponsor, success begins with early preparation, clear communication, and structured documentation. With these foundations, your first-in-human IND can be more than just a submission — it can be a launchpad for innovation.